Provided by Tiger Trade Technology Pte. Ltd.

Quince Therapeutics, Inc.

0.5278
+0.3978305.96%
Post-market: 0.4999-0.0279-5.28%16:29 EST
Volume:1.48B
Turnover:532.24M
Market Cap:29.39M
PE:-0.44
High:0.6520
Open:0.2834
Low:0.2459
Close:0.1300
52wk High:4.55
52wk Low:0.1251
Shares:55.68M
Float Shares:49.56M
Volume Ratio:121.68
T/O Rate:2983.58%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.2092
EPS(LYR):-1.3136
ROE:-247.78%
ROA:-22.10%
PB:27.75
PE(LYR):-0.40

Loading ...

Why Is Quince Therapeutics Stock (QNCX) Up Today?

TIPRANKS
·
Yesterday

Why Is Quince Therapeutics Stock Soaring Tuesday?

Benzinga
·
Yesterday

Quince Therapeutics Engages LifeSci Capital to Pursue Strategic Alternatives

Reuters
·
Yesterday

Quince Therapeutics Engages Lifesci Capital as Its Exclusive Financial Advisor to Explore Strategic Alternatives

THOMSON REUTERS
·
Yesterday

Five Directors Resign from Quince Therapeutics Board

Reuters
·
Feb 03

Quince Therapeutics Cut to Hold From Buy by D. Boral Capital

Dow Jones
·
Jan 30

Quince Ends Development of Lead Drug Candidate; Shares Slide

Dow Jones
·
Jan 30

BUZZ-Quince Therapeutics drops after co's drug fails to meet main goal in late-stage trial

Reuters
·
Jan 30

Quince down 14% after NEAT study endpoint did not reach statistical significance

TIPRANKS
·
Jan 30

Quince Therapeutics trading halted, news pending

TIPRANKS
·
Jan 30

Quince Therapeutics Ends Development of eDSP After Phase 3 Trial Misses Key Endpoints

Reuters
·
Jan 30

Quince Therapeutics - to Cease Clinical Development of Edsp

THOMSON REUTERS
·
Jan 30

Quince Therapeutics - Edsp Well Tolerated With No Safety Concerns

THOMSON REUTERS
·
Jan 30

Quince Therapeutics - Primary and Secondary Endpoints Did Not Achieve Statistical Significance

THOMSON REUTERS
·
Jan 30

Quince Therapeutics Announces Topline Results From Pivotal Phase 3 Neat Clinical Trial of Edsp in Ataxia-Telangiectasia

THOMSON REUTERS
·
Jan 30

NASDAQ TRADE HALT HALT NEWS PENDING AT 03:06 PM

Reuters
·
Jan 30

Quince Therapeutics Reports Long-Term Safety Data for eDSP in Children with Ataxia-Telangiectasia

Reuters
·
Jan 29

Nasdaq Net Change Percentage Gainers & Losers

Dow Jones
·
Jan 21

Quince Therapeutics Director Luca Benatti Reports Sale of Common Shares

Reuters
·
Dec 30, 2025

BRIEF-Quince Marks Final Patient Visit in NEAT Phase 3 Study

Reuters
·
Dec 15, 2025